InsiderTrades

Form 4 for ABOS Acumen Pharmaceuticals, Inc.

Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001209191-21-046029 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-07-08 2021-07-06 ABOS OConnell Daniel Joseph Pres, CEO, Dir X - OptEx $4.47 +35 1,577 +2% +$156.45
D 2021-07-08 2021-07-06 ABOS OConnell Daniel Joseph Pres, CEO, Dir C - Cnv Deriv — +123 1,542 +9% —
D 2021-07-08 2021-07-06 ABOS OConnell Daniel Joseph Pres, CEO, Dir F - Tax $16.00 -10 1,567 -0.6% -$160
D 2021-07-08 2021-07-06 ABOS OConnell Daniel Joseph Pres, CEO, Dir M - OptEx $0.00 -35 0 -100% $0
D 2021-07-08 2021-07-06 ABOS OConnell Daniel Joseph Pres, CEO, Dir C - Cnv Deriv — -123 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-06 X A 35 $4.47 1,577 D — —
2 Common Common Stock 2021-07-06 C A 123 — 1,542 D — — (F1) On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
3 Common Common Stock 2021-07-06 F D 10 $16.00 1,567 D — —
4 Derivative Warrant (Right to Buy) 2021-07-06 M D 35 $0.00 0 D $4.47 · 2020-12-31 to 2025-06-30 35 Common Stock
5 Derivative Series A Preferred Stock 2021-07-06 C D 123 — 0 D — · — to — 123 Common Stock (F1) On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.